# ATG Individualized Dosing Model in URD-PBSCT.

> **NCT06572462** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cytomegalovirus Infections
- Infection Reactivation
- Stem Cell Transplant Complications

## Interventions

- **DRUG:** individualized ATG dosing strategy

## Key facts

- **NCT ID:** NCT06572462
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-31
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06572462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06572462, "ATG Individualized Dosing Model in URD-PBSCT.". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06572462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*